The O-RAN Alliance Announces New Board Members
The O-RAN Alliance announced today that Reliance Jio, TIM, and Verizon have joined the O-RAN board.
“It’s encouraging to see the O-RAN Alliance off to such a strong start and gaining momentum as we welcome three new board members. It’s important that the wireless industry continues to come together to drive forward O-RAN’s goals for open networking, software, and virtualization in global wireless networks especially as 5G is closer than ever,” said Andre Fuetsch, Chairman of the O-RAN Alliance, President-AT&T Labs and CTO of AT&T.
“This is a great opportunity for the Service Provider Industry as network, services and applications leverage cloud native platforms and the right time to fundamentally transform the RAN infrastructure and platforms. We look forward to working closely with the O-RAN Alliance in the acceleration and adoption of open, intelligent, and programmable RAN architectures that can clearly disrupt the building blocks of 5G and beyond,” said Mathew Oommen, President, Reliance Jio. “Jio is excited to play a leadership role within O-RAN and we look forward to working with all the Alliance Partners in shaping the foundation of future networks around the globe.”
“We are very excited by the opportunity for O-RAN to extend the strength of open solutions to the mobile industry,” said Elisabetta Romano, TIM CTO. “TIM is a strong supporter of collaborative communities and standards, and we think that open RAN will be a very important part in the big 5G transformation that is coming. We will also contribute to O-RAN’s work with our mmWave Testing Lab in Torino, one of the first in Europe.”
“We are excited to continue our drive towards an open radio network specification for the wireless industry,” said Ed Chan, Senior Vice President and Chief Technology Architect of Verizon. “We will leverage the foundational success of xRAN to accelerate the work in O-RAN. Verizon looks forward to contributing to the success of O-RAN in realizing network components' interoperability at a global scale to create the next generation of flexible wireless networks for our customers."
O-RAN is organized as a series of work groups focused on specific aspects of the RAN open architecture and interfaces, with a Technical Steering Committee (TSC) coordinating the overall work program.
“We are pleased with the smooth transition of both C-RAN Alliance and xRAN Forum contributors into the O-RAN Alliance work groups,” said Dr. Sachin Katti, Professor at Stanford University and O-RAN Alliance TSC Co-Chair. “We’ve seen advancement on all fronts. The mix of new contributors and ideas promises to accelerate our progress during this next phase of O-RAN Alliance specifications and reference designs.”
O-RAN has released its inaugural white paper, “O-RAN: Towards an Open and Smart RAN,” which is available on the O-RAN website. The white paper describes the O-RAN architecture, which drives a more cost-effective, intelligent RAN with open interoperable interfaces for next generation 5G networks and beyond.
“It is an exciting launching pad, building upon the accomplishments of both C-RAN and xRAN communities,” said Chih-Lin I, Chief Scientist of China Mobile and TSC Co-Chair of O-RAN. “This white paper is the fruit of a joint effort from 7 working groups and 12 board members of the O-RAN Alliance. The paper identifies an AI-enabled RAN Intelligent Controller, RAN Virtualization, Open Interfaces, Whitebox Hardware, and Open Source Software as key focus areas. The architecture and roadmap provide clear guidelines for the industry and helps build the momentum to accelerate the necessary transformation towards a sustainable ecosystem.”
The O-RAN Alliance held a series of technical meetings and a symposium, with over 200 people from 80 companies participating. The symposium included speakers from leading operators and industry suppliers.
O-RAN has also started collaboration arrangements with The Linux Foundation to establish an open source software community for the creation of open source RAN software. Collaboration with The Linux Foundation will enable the creation of open source software supporting the O-RAN architecture and interfaces.
“We are excited to see alignment on this exciting area of technology,” said Arpit Joshipura, general manager, Networking, The Linux Foundation. “Our joint efforts will help accelerate the creation, integration, and deployment of open source in the RAN.”
About O-RAN Alliance
The O-RAN Alliance is a world-wide, carrier-led effort to drive new levels of openness in the radio access network of next generation wireless systems. Future RANs will be built on a foundation of virtualized network elements, white-box hardware and standardized interfaces that fully embrace O-RAN’s core principles of intelligence and openness. An ecosystem of innovative new products is already emerging that will form the underpinnings of the multi-vendor, interoperable, autonomous RAN, envisioned by many in the past, but only now enabled by the global industry-wide vision, commitment and leadership of O-RAN Alliance members and contributors. More information about O-RAN can be found at www.o-ran.org.
About The Linux Foundation
The Linux Foundation is the organization of choice for the world’s top developers and companies to build ecosystems that accelerate open technology development and industry adoption. Together with the worldwide open source community, it is solving the hardest technology problems by creating the largest shared technology investment in history. Founded in 2000, The Linux Foundation today provides tools, training and events to scale any open source project, which together deliver an economic impact not achievable by any one company. More information can be found at www.linuxfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181211005244/en/
Contact information
O-RAN PR Contact
Rod Stuhlmuller
pr@o-ran.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom